ISPOR 19TH ANNUAL EUROPEAN CONGRESS EXAMINES INCLUSION OF FUTURE MEDICAL COSTS IN HEALTH TECHNOLOGY ASSESSMENT GUIDELINES

Published Nov 2, 2016
Vienna, Austria—2 November 2016—The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) held an issue panel entitled, Should Health Technology Assessment Guidelines Recommend Inclusion of Future Medical Costs?, at the Society’s 19th Annual European Congress in Vienna, Austria.  The issue panel was moderated by Andrew Briggs, DPhil, MSc, William R, Lindsay Chair of Health Economics and Professor of Health Economics, University of Glasgow, Glasgow, UK. Panelists for the issue panel included:
  • Alec Morton, PhD, Professor, Management Science, University of Strathclyde, Glasgow, UK
  • Pieter van Baal, PhD, Associate Professor, Institute for Health Policy and Management, Erasmus University Rotterdam, Rotterdam, The Netherlands
  • Ad Antonisse, MSc, Director Economic Affairs (Market Access and Public Affairs), AstraZeneca, Zoetermeer, The Netherlands
This session explored whether health technology assessment (HTA) guidelines should recommend the inclusion of “unrelated future costs” of a medical technology. Recently, Dutch HTA guidelines were changed to recommend inclusion of future, unrelated medical costs. Currently, however, many HTA guidelines exclude future medical costs from an appraisal. For example, the costs of caring for a patient with dementia after preventing death from stroke would not be included in a cost effectiveness analysis of a thrombolysis treatment. The panelists presented the benefits and disadvantages of including future, unrelated costs in HTA guidelines. Alec Morton, PhD provided a summary of theoretical arguments for and against inclusion of future unrelated medical costs. Pieter van Baal, PhD reviewed approaches for how these future costs can be estimated in practice. Ad Antonisse, MSc provided the industry perspective on the issue. Additional information on the ISPOR 19th Annual European Congress can be found here. Released presentations from the congress can be found here. Interested parties can follow news and developments from the conference on social media using the hashtag #ISPORVienna.

###

Related Stories

ISPOR Task Force Addresses Critical Gap in Surrogate Endpoint Guidance

May 28, 2026

Value in Health, announced the publication of an ISPOR Good Practices Report providing guidance on the use of surrogate endpoint evaluation methods in health technology assessment (HTA) decision making. The report, “Methods for Evaluation of Surrogate Endpoints for HTA Decision Making: A Good Practices Report of an ISPOR Task Force,” was published in the May 2026 issue of Value in Health.

How Is Health Valued in the United Kingdom? We Finally Have a Better Answer

May 27, 2026

Value in Health, the official journal of ISPOR—The Professional Society for Health Economics and Outcomes Research, announced today the publication of a pair of companion articles that together establish both the methodological foundation of the first definitive UK value set for the EQ-5D-5L and the practical implications of adopting it—thus equipping health technology assessment decision makers with a UK value set suitable for informing policy. The articles were featured in the May 2026 issue of Value in Health.

ISPOR Announces 2026-2027 Board of Directors

May 26, 2026

ISPOR—The Professional Society for Health Economics and Outcomes Research announced its 2026-2027 board of directors who will assume office on July 1, 2026.
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×